Affiliation:
1. Department of Clinical Biomaterial Applied Science, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan
Abstract
Induced pluripotent stem cells (iPSCs) have become a prevalent topic after their discovery, advertised as an ethical alternative to embryonic stem cells (ESCs). Due to their ability to differentiate into several kinds of cells, including cardiomyocytes, researchers quickly realized the potential for differentiated cardiomyocytes to be used in the treatment of heart failure, a research area with few alternatives. This paper discusses the differentiation process for human iPSC-derived cardiomyocytes and the possible applications of said cells while answering some questions regarding ethical issues.
Funder
Takeda Science Foundation
Reference168 articles.
1. Reducing the Global Burden of Cardiovascular Disease, Part 1;Joseph;Circ. Res.,2017
2. Sodium channel mutations and arrhythmias;Ruan;Nat. Rev. Cardiol.,2009
3. Mechanisms of cardiac regeneration;Uygur;Dev. Cell,2016
4. Cells or drugs? The race to regenerate the heart;Plackett;Nature,2021
5. Engineering human cardiac muscle patch constructs for prevention of post-infarction LV remodeling;Wang;Frontiers,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献